Articles related to INFLUENZA

The FDA approved Moderna’s mFLUSIVA, the first mRNA influenza vaccine, for adults aged 50 and older. Availability is expected during the 2026–2027 respiratory virus season, with confirmatory evidence pending for adults 65 and older.

ACOG released its first maternal immunization schedule formally diverging from federal vaccine recommendations, following its February 2026 withdrawal from the CDC Advisory Committee on Immunization Practices over concerns about the committee’s scientific integrity.

Investigators surmised that current influenza vaccination programs provide substantial protection but could be further improved by strategies that could mitigate repeat vaccination effects.

Provision of antiviral therapy does not require a positive test for influenza when influenza is circulating in the community.

Based on the data presented, the committee agreed that there was a need to change the influenza A/H3N2 virus strains from the 2024-2025 formula.

Antiviral therapy initiated within 48 hours of symptom onset can reduce illness duration by 1-2 days, highlighting the importance of early recognition and intervention in high-risk populations.